Dr. Rodrigo Sanchez-Bayona presented a clinical case of a 61-year-old postmenopausal woman with stage 4 luminal breast cancer, discussing her initial treatment with letrozole plus ribociclib, subsequent disease progression, and the decision to switch to fulvestrant plus everolimus based on biomarker testing.
0:34 - Introduction and Case Presentation: a 61-year-old postmenopausal woman with hormone receptor-positive, HER2-negative metastatic breast cancer.
3:07 - Treatment Initiation and Response: Discussion on the initiation of first-line treatment with letrozole plus ribociclib and the patient's initial positive response, followed by disease progression after nine months.
7:00 - Second-Line Treatment Decision: Considerations for rebiopsy, biomarker analysis, and the decision to proceed with fulvestrant plus everolimus due to the patient's endocrine resistance and specific mutations.